What are the potential interactions between pregabalin and eperisone in adults with a history of neurological or chronic pain conditions and possibly musculoskeletal issues, particularly those with impaired renal function or taking other central nervous system (CNS) depressants?

Pregabalin and Eperisone Interaction

Direct Answer

There are no documented pharmacokinetic or pharmacodynamic drug-drug interactions between pregabalin and eperisone, but their combined use creates significant additive CNS depressant effects that substantially increase the risk of sedation, dizziness, falls, and confusion—particularly in elderly patients, those with renal impairment, or individuals taking other CNS depressants.

---

Mechanism of Additive CNS Depression

Why This Combination Is Problematic

• Pregabalin binds to the alpha-2-delta subunit of voltage-gated calcium channels, reducing excitatory neurotransmitter release and causing dose-dependent CNS depression 1
• Eperisone is a centrally-acting muscle relaxant that produces CNS depression through its muscle-relaxing and sedative properties
• The 2019 AGS Beers Criteria explicitly warns that combining CNS-active drugs (including gabapentinoids and muscle relaxants) increases the risk of falls, respiratory depression, cognitive impairment, and death in older adults 2
• Both medications independently cause dizziness (pregabalin: 23-46%), somnolence (pregabalin: 15-25%), and gait disturbances, with effects being additive rather than synergistic when combined 3

---

Critical Risk Factors That Amplify Danger

Renal Impairment

• Pregabalin is 95% renally excreted unchanged, and in acute renal failure, the area under the curve increases 6.3-fold with terminal half-life doubling to 28 hours 4, 1
• Mandatory dose reduction is required: reduce total daily dose by 50% for creatinine clearance 30-60 mL/min, 75% for 15-30 mL/min, and 85-90% for <15 mL/min 3
• Calculate creatinine clearance using the Cockcroft-Gault equation before initiating pregabalin, as age-related decline in renal function is often masked by normal serum creatinine due to reduced muscle mass 3
• In hemodialysis patients, gabapentin (pregabalin's analog) was associated with 50% higher hazards of altered mental status, 55% higher hazards of falls, and 38% higher hazards of fractures even at low doses 5

Elderly Patients

• Lower starting doses and slower titration are mandatory in elderly patients due to increased risk of dizziness, somnolence, confusion, balance disorder, tremor, and coordination abnormalities 3
• The 2024 AHA guidelines specifically warn that anxiolytics and sedating medications significantly increase fall risk when combined with cardiovascular medications such as antihypertensives and diuretics 2
• Elderly patients are more susceptible to falls, confusion, and sedation from gabapentinoids, particularly when combined with other CNS-active drugs 3

Concomitant CNS Depressants

• The 2022 CDC guidelines note that pregabalin combined with opioids, benzodiazepines, or other CNS depressants causes serious breathing problems and synergistic sedative effects 2, 3
• The 2019 AGS Beers Criteria recommends minimizing the total number of CNS-active drugs used together, as each additional agent compounds the risk 2

---

Specific Dosing Modifications When Combining These Agents

If Combination Is Clinically Necessary

• Start pregabalin at 25-50 mg/day (not the standard 75 mg twice daily) with slow weekly titration to target 150-300 mg/day maximum when combined with eperisone 3
• Use the lowest effective dose of eperisone (typically 50 mg three times daily rather than higher doses)
• Implement slow weekly titration with adequate intervals (minimum 7 days between increases) to monitor for cumulative sedative effects 3
• Never exceed pregabalin 300 mg/day when combined with muscle relaxants in elderly patients or those with any degree of renal impairment 3

Monitoring Requirements

• Assess for dizziness, somnolence, gait disturbance, and confusion at each dose escalation
• Evaluate fall risk using standardized tools (Timed Up and Go test, Berg Balance Scale) before initiating combination and after each dose change
• Monitor renal function (creatinine clearance) at baseline, 2 weeks, 1 month, and then every 3 months during combination therapy 3
• Educate patients to avoid driving or operating machinery until they know how the combination affects them

---

Safer Alternative Strategies

Sequential Rather Than Concurrent Use

• Consider using pregabalin for neuropathic pain and reserving eperisone for acute musculoskeletal exacerbations rather than chronic concurrent use
• The 2024 AHA guidelines recommend less-sedating muscle relaxants (methocarbamol, metaxalone) over more sedating options when CNS-active drugs are already prescribed 2

Combination With Non-Sedating Agents

• The Mayo Clinic guidelines demonstrate that combining pregabalin with nortriptyline (a tricyclic antidepressant) has proven superiority over pregabalin monotherapy in randomized controlled trials 3
• Combining pregabalin with topical agents (lidocaine, diclofenac, capsaicin) provides multimodal analgesia without additive CNS depression 2

---

Critical Pitfalls to Avoid

• Do not assume "no interaction" means "safe to combine"—the absence of pharmacokinetic interaction does not negate the clinically significant additive pharmacodynamic effects 2
• Do not use standard pregabalin starting doses (75 mg twice daily) when combining with muscle relaxants—this dramatically increases adverse event risk 3
• Do not fail to calculate creatinine clearance before initiating pregabalin, especially in patients over 65 years—serum creatinine alone is unreliable 3
• Do not combine three or more CNS-active drugs (pregabalin + eperisone + opioid/benzodiazepine) without specialist consultation, as this creates unacceptable sedative burden 2, 3
• Do not abruptly discontinue either medication—taper pregabalin gradually over minimum 1 week to avoid withdrawal symptoms 3

---

When to Avoid This Combination Entirely

• Patients with creatinine clearance <30 mL/min should not receive standard doses of pregabalin when combined with muscle relaxants 3
• Patients with history of falls, syncope, or orthostatic hypotension should avoid this combination 2
• Patients concurrently taking opioids, benzodiazepines, or other sedating medications should not add both pregabalin and eperisone 2
• Frail elderly patients (Clinical Frailty Scale ≥6) should use alternative non-sedating strategies 2